Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
ENDOCYTE INC (ECYT) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/21/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Endocyte, Inc., effective December 21, 2018",
"Amended and Restated Bylaws of Endocyte, Inc., effective December 21, 2018",
"Form of Amendment to Change in Control and Severance Agreement"
12/17/2018 8-K Other Events
12/03/2018 8-K Other Events
11/07/2018 8-K Quarterly results
Docs: "Endocyte Provides Third Quarter 2018 Financial Results and Operational Update"
10/18/2018 8-K Quarterly results
09/12/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among the Company and Jefferies LLC, Wells Fargo Securities, LLC, and RBC Capital Markets, LLC, as representatives of the several underwriters named in Schedule A thereto",
"Opinion of Faegre Baker Daniels LLP"
09/10/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval"
07/31/2018 8-K Quarterly results
Docs: "Endocyte Provides Second Quarter 2018 Financial Results and Operational Update -Initiated phase 3 VISION study of 177Lu-PSMA-617 in mCRPC- -Secured commercial supply of no-carrier-added Lutetium-177 through 2035-"
07/11/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Global Supply Agreement, between Endocyte, Inc. and ITG Isotope Technologies Garching GmbH",
"Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177 – Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 –"
05/09/2018 8-K Quarterly results
Docs: "Endocyte Provides First Quarter 2018 Financial Results and Operational Update – Recently Updated Phase 2 Data on 177Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress –"
03/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments –Dawn Svoronos, Former President of Merck’s Europe/Canada Region, Brings Significant Commercial Leadership and Board Experience –"
03/02/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors –Patrick Machado, Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space –"
02/28/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and among the Company and Jefferies LLC, Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc., as representatives of the several underwriters named in Schedule A thereto",
"Opinion of Faegre Baker Daniels LLP"
02/26/2018 8-K Quarterly results
Docs: "Website Information"
11/06/2017 8-K Quarterly results
Docs: "Website Information"
10/02/2017 8-K Quarterly results
08/08/2017 8-K Quarterly results
Docs: "Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update - Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 –"
06/02/2017 8-K Form 8-K - Current report
05/10/2017 8-K Form 8-K - Current report
05/05/2017 8-K Form 8-K - Current report
03/10/2017 8-K Form 8-K - Current report
02/21/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
10/20/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/11/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
06/20/2016 8-K Form 8-K - Current report
05/09/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
04/20/2016 8-K Form 8-K - Current report
04/19/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research Annual Meeting 2016"
03/02/2016 8-K Quarterly results
Docs: "Endocyte Reports Fourth Quarter and Year End 2015 Financial Results and Provides Clinical and Pipeline Update"
01/05/2016 8-K Regulation FD Disclosure
11/03/2015 8-K Quarterly results
Docs: "Endocyte, Inc. Statements of Operations For the Three Months Ended September 30, For the Nine Months Ended September 30, 2014 2015 2014 2015 Collaboration revenue $ 3,904 $ 33 $ 70,341 $ 58 Costs and expenses: Research and development 5,675 6,582 37,652 19,923 General and administrative 4,007 3,776 19,476 12,207 Total costs and expenses 9,682 10,358 57,128 32,130 Income from operations 13,213 Interest income, net 161 153 414 490 Other income , net 170 106 Net income $ $ $ 13,540 $ Net income per share: Basic $ $ $ 0.34 $ Diluted $ $ $ 0.33 $ Comprehensive income $ $ $ 13,408 $ Weighted average number of common shares used in net income per share: Basic 41,564,840 41,974,518 39,738,685 41,924,252 Diluted 41,564,840 41,974,518 41,493,711 41,924,252 Endocyte, Inc. Balance Sheets"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy